• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

AMILORIDE Drug Record

  • Summary
  • Interactions
  • Claims
  • AMILORIDE chembl:CHEMBL945 ApprovedAntineoplastic

    Alternate Names:

    HYDRO-RIDE
    MIDAMOR
    AMILORIDE
    AMILORID
    AMIPRAMIDIN
    AMIPRAMIDINE
    MIDAMOR®
    AMYLORIDE
    AMILORIDA
    AMILORIDUM
    3,5-DIAMINO-N-CARBAMIMIDOYL-6-CHLOROPYRAZINE-2-CARBOXAMIDE
    AMILORIDE HCL
    N-AMIDINO-3,5-DIAMINO-6-CHLOROPYRAZINECARBOXAMIDE
    chemidplus:2609-46-3
    chembl:CHEMBL945
    drugbank:00594
    rxcui:644
    pubchem.compound:16231

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antihypertensive agent
    Drug Class diuretics
    Year of Approval 1981
    Drug Class antihypertensive agents
    (2 More Sources)

    Publications:

    Sugiura et al., 2005, Acid-sensing properties in rat gastric sensory neurons from normal and ulcerated stomach., J. Neurosci.
    Jones et al., 2004, Acid-induced pain and its modulation in humans., J. Neurosci.
    Petruska et al., 2002, Chemical responsiveness and histochemical phenotype of electrophysiologically classified cells of the adult rat dorsal root ganglion., Neuroscience
    Xiong et al., 2006, Ca2+ -permeable acid-sensing ion channels and ischemic brain injury., J. Membr. Biol.
    Wang et al., 2006, Calcium-permeable acid-sensing ion channel is a molecular target of the neurotoxic metal ion lead., J. Biol. Chem.
    Kelly et al., 2003, Characterization of an amiloride binding region in the alpha-subunit of ENaC., Am. J. Physiol. Renal Physiol.
    Otulakowski et al., 2007, Steroid and oxygen effects on eIF4F complex, mTOR, and ENaC translation in fetal lung epithelia., Am. J. Respir. Cell Mol. Biol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Ji et al., 2004, Degenerin sites mediate proton activation of deltabetagamma-epithelial sodium channel., J. Biol. Chem.
    Thorn CF et al., 2013, PharmGKB summary: Diuretics pathway, pharmacodynamics., Pharmacogenet Genomics
    Yamagata et al., The impact of phorbol ester on the regulation of amiloride-sensitive epithelial sodium channel in alveolar type ii epithelial cells., Exp. Lung Res.
    Ludwig et al., 2004, Pseudohypoaldosteronism type 1 and the genes encoding prostasin, alpha-spectrin, and Nedd4., Int. J. Mol. Med.
    Viemann et al., 2001, Evidence for genetic heterogeneity of pseudohypoaldosteronism type 1: identification of a novel mutation in the human mineralocorticoid receptor in one sporadic case and no mutations in two autosomal dominant kindreds., J. Clin. Endocrinol. Metab.
    Iwai et al., 2001, Association of sodium channel gamma-subunit promoter variant with blood pressure., Hypertension
    Akçay et al., Pseudohypoaldosteronism type 1 and respiratory distress syndrome., J. Pediatr. Endocrinol. Metab.
    Yamamura et al., 2005, Evans blue is a specific antagonist of the human epithelial Na+ channel delta-subunit., J. Pharmacol. Exp. Ther.
    Yamamura et al., 2005, Icilin activates the delta-subunit of the human epithelial Na+ channel., Mol. Pharmacol.
    Ji et al., 2004, The role of Pre-H2 domains of alpha- and delta-epithelial Na+ channels in ion permeation, conductance, and amiloride sensitivity., J. Biol. Chem.
    Ji et al., 2006, Delta-subunit confers novel biophysical features to alpha beta gamma-human epithelial sodium channel (ENaC) via a physical interaction., J. Biol. Chem.
    Yamamura et al., 2004, Protons activate the delta-subunit of the epithelial Na+ channel in humans., J. Biol. Chem.
    Brooks et al., 2002, Targeted proteomic profiling of renal Na(+) transporter and channel abundances in angiotensin II type 1a receptor knockout mice., Hypertension
    Lebowitz et al., 2003, Effect of altered Na+ entry on expression of apical and basolateral transport proteins in A6 epithelia., Am. J. Physiol. Renal Physiol.
    Planès et al., 2005, In vitro and in vivo regulation of transepithelial lung alveolar sodium transport by serine proteases., Am. J. Physiol. Lung Cell Mol. Physiol.
    Kamide et al., 2004, Six missense mutations of the epithelial sodium channel beta and gamma subunits in Japanese hypertensives., Hypertens. Res.
  • AMILORIDE   ASIC1

    Interaction Score: 46.37

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    15758172 15574747 12401318 16685601 16319075


    Sources:
    TTD

  • AMILORIDE   SCNN1D

    Interaction Score: 27.05

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name HTI-101
    Novel drug target Established target

    PMIDs:
    16107516 16033954 14660613 16423824 14726523


    Sources:
    TdgClinicalTrial TEND

  • AMILORIDE   SCNN1G

    Interaction Score: 17.39

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name HTI-101
    Novel drug target Established target

    PMIDs:
    12396248 15547682 11344206 11463765 12503866 23788015


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • AMILORIDE   SCNN1A

    Interaction Score: 15.46

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name HTI-101
    Novel drug target Established target

    PMIDs:
    12928313 17556672 11752352 15084585 23788015


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • AMILORIDE   SCNN1B

    Interaction Score: 11.59

    Interaction Types & Directionality:
    blocker (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name HTI-101
    Novel drug target Established target

    PMIDs:
    23788015 11882592 12746257 12396248 15681398 15198480


    Sources:
    TdgClinicalTrial TEND PharmGKB

  • AMILORIDE   CYP4A11

    Interaction Score: 3.86

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • AMILORIDE   HSD17B10

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • AMILORIDE   EHMT2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: AMILORIDE

    • Version: 01-August-2011

    Alternate Names:
    AMILORIDE Primary Drug Name

    Drug Info:
    Drug Class antihypertensive agents
    Year of Approval 1981
    Drug Class diuretics

    Publications:

  • TdgClinicalTrial: AMILORIDE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antihypertensive agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • PharmGKB: amiloride

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Thorn CF et al., 2013, PharmGKB summary: Diuretics pathway, pharmacodynamics., Pharmacogenet Genomics

  • DTC: AMILORIDE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL945 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Amiloride

    • Version: 2020.06.01

    Alternate Names:
    D0I0RJ TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL945

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21